A Phase II study of Aprepitant in patients receiving chemotherapy included carboplatin for gynecological canncer.

A Phase II study of Aprepitant in patients receiving chemotherapy included carboplatin for gynecological canncer. - A Phase II study of Aprepitant in patients receiving chemotherapy included carboplatin for gynecological canncer.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005020

Enrollment

150

Registered

2011-02-04

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynecological cancer

Interventions

Azasetron 10mg(d1) + dexamethasone(d1-3) + aprepitant(d1-3) Azasetron 10mg(d1) + dexamethasone(d1-3)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Gynecological cancer 2. Received the chemotherapy including carboplatin.

Exclusion criteria

Exclusion criteria: 1. Dysfunction of liver 2. Vomiting prior to chemotherapy 3. Antiemetic use prior to chemotherapy 4. Pregnant or lactating women or women of childbearing potential 5. Hypersensitivity for Aprepitant 6. Under treatment used antiallergic agents or corticosteroid 7. patients with emetic factor except for chmotherapy 8. Patients judged inappropriate for this study by physicians

Design outcomes

Primary

Measure	Time frame
the proportion of patients with no emesis in the overall phase (120 hour after administration of carboplatin).	—

Secondary

Measure	Time frame
the proportion of patients with no emesis in the acute phase (24 hour after administration of carboplatin) and delay phase (120 hour)	—

Countries

Japan

Contacts

Public ContactMasafumi Koshiyama

Kyoto University Graduate School of Medicine Department of Gynecology and Obstetrics

babatsu@kuhp.kyoto-u.ac.jp0757513269

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026